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In the European Intergroup EURO-LB02 trial, children and adoles-cents with lymphoblastic lymphoma underwent the non-Hodgkinlymphoma Berlin-Frankfurt-Münster protocol without prophylactic
cranial radiotherapy. The primary aims of this trial were to test
whether replacing prednisone with dexamethasone during induction
increases event-free survival in the subgroups with T-cell lymphoblas-
tic lymphoma and whether therapy duration could be reduced from 24
to 18 months (factorial design, randomizations). These questions could
not be answered due to premature closure of the trial. Here we report
on the secondary aims of the trial: whether the results of the NHL-
BFM90 study could be reproduced and evaluation of disease features
and prognostic factors. Three hundred and nineteen patients (66 with
precursor B-cell lymphoblastic lymphoma, 233 with T-cell lymphoblas-
tic lymphoma, 12 with mixed phenotype, 8 not classifiable) were
enrolled. In induction, 215 patients received prednisone and 104
patients received dexamethasone. The median follow-up was 6.8 years
(range, 3.0-10.3). The 5-year event-free survival was 82±2% [12 toxic
deaths, 5 secondary malignancies, 43 non-response/relapse (central
nervous system n=9; all received prednisone during induction)]. The
event-free survival rate was 80±5% for patients with precursor B-cell
lymphoblastic lymphoma, 82±3% for those with T-cell lymphoblastic
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ABSTRACT
Some results were presented at the 4th International Symposium on Childhood, Adolescent and Young Adult Non-
Hodgkin Lymphoma, New York, NY, USA, Nov. 1-3, 2012. Part of the data were presented at the 14th International
Conference on Malignant Lymphoma in Lugano, Switzerland, June 17-20, 2015. 
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Introduction
Although lymphoblastic lymphoma (LBL) is an orphan
disease, it is the second most frequent non-Hodgkin lym-
phoma (NHL) observed in children and adolescents. Acute
lymphoblastic leukemia (ALL)-type therapeutic strategies
have been demonstrated to be efficacious in LBL.
Treatment protocols derived from the Berlin-Frankfurt
Münster (BFM) group ALL strategy result in event-free sur-
vival rates of 75% to 90%. These survival rates are, howev-
er, achieved at the expense of considerable toxicity.1-7 On
the other hand, children who do not respond to this treat-
ment or who relapse after it still have an extremely poor
chance of surviving.8 Thus, many questions regarding opti-
mal treatment of childhood LBL remain to be clarified. 
Although LBL and ALL are biologically similar, they prob-
ably represent different diseases, as suggested by recent
research,9-12 and advances achieved in the optimization of
childhood ALL treatment cannot be adopted as LBL treat-
ment strategies. In particular, meaningful parameters allow-
ing risk-adapted therapies, such as chromosomal transloca-
tions and minimal residual disease monitoring,13,14 are not
yet available for LBL. 
The lack of meaningful prognostic parameters for child-
hood LBL is mostly explained by the nature of the disease
and the limited number of patients who are treated uni-
formly. In contrast to ALL, peripheral blood and bone mar-
row are limited sources of tumor cells. More extensive sur-
gery to obtain appropriate tumor material for biological
studies, may not be feasible given the often life-threatening
condition of the patients at initial presentation. Thus, even
the immunological classification of the lymphoma is not
exact in some cases. 
The EURO-LB 02 study was the second inter-group clin-
ical trial of the newly established European Intergroup
Cooperation on Childhood and Adolescent NHL (EIC-
NHL). The patients were diagnosed and classified according
to a standardized work-up, including a central pathology
review. The treatment strategy of the trial was adapted
from the NHL-BFM90 study, with the omission of prophy-
lactic cranial irradiation.3,15 The primary aims of the EURO-
LB02 study were to test, in a randomized manner, whether
replacing prednisone with dexamethasone during the
induction phase increases event-free survival (EFS) in the
subgroup of patients with T-cell LBL (T-LBL) and whether
therapy duration could be reduced from 24 to 18 months
(factorial design). We could not answer these questions
because the trial had to be closed prematurely due to a sub-
stantial number of toxic deaths.
Here we report on the results of the secondary aims of
this study: to determine whether the outstanding results
for patients with T-LBL in the NHL-BFM90 study could
be reproduced in a large European inter-group trial, to
assess features of the disease, and to evaluate prognostic
factors. Furthermore, we provide comprehensive infor-
mation on toxicity and specific caveats regarding this
treatment strategy, which is currently the backbone of
LBL therapy in many countries. The trial is registered at
http://www.clinicaltrials.gov (clinicaltrials.gov identifier:
#NCT00275106).
Methods
Patients
Patients <22 years old with newly diagnosed LBL were eligible
for entry into the study. Patients with T-LBL (local assessment)
were eligible for the first randomization. For participation in the
second randomization, T-LBL had to have been confirmed by the
national reference laboratory. Further exclusion criteria are listed in
Online Supplement 2. 
Diagnostic work-up
The diagnosis of LBL was established by tumor biopsy and/or
cytological and immunological examinations of malignant effu-
sions. A review by national reference pathologists or national ref-
erence cytomorphology/immunophenotyping laboratories was
requested for all patients. Minimal diagnostic requirements and
staging procedures are outlined in Online Supplements 3 and 4. 
Treatment plan and responses
Chemotherapy was based on the NHL-BFM90 protocol (Table
1).5 Patients with non-T-cell LBL received standard treatment strat-
ified according to stage and central nervous system (CNS) status,
whereas the treatments were randomized in patients with T-LBL
(Table 1 and Figure 1A,B). CNS-positive patients received cranial
radiotherapy after re-intensification. Online Supplements 5 and 6
contain recommendations on infection prophylaxis and details
regarding the randomization process. Response criteria are out-
lined in Online Supplement 7.
Study design and statistics
EURO-LB02 was conducted by eight national/multinational
cooperative study groups in 14 European countries. 
The primary endpoint for both study questions was EFS, com-
puted as the time from randomization to date of the last follow-up
visit or the first event, i.e., a non-response on day 33 (defined as
>5% blasts in the bone marrow and/or blasts in the cerebrospinal
fluid) and/or <35% tumor regression), relapse, secondary malig-
nancy, or death from any cause. 
The power and sample size calculations are detailed in Online
Supplement 8.
lymphoma, and 100% for patients with a mixed phenotype. During induction, significantly more
grade III/IV toxicities were observed in patients receiving dexamethasone, resulting in significant treat-
ment delays. The number of toxic deaths did not differ significantly. The only variable associated with
outcome was performance status at diagnosis. The 90% event-free survival rate for patients with T-
cell lymphoblastic lymphoma shown in study NHL-BFM90 was not replicated, mainly due to more
toxic deaths and central nervous system relapses. Dexamethasone in induction may prevent central
nervous system relapse more effectively than prednisone but produces a higher burden of toxicity.
(#NCT00275106).
The secondary endpoints were overall survival and toxicity.
Overall survival was calculated as the time from randomization to
the date of death or the last follow-up visit. 
EFS and overall survival were estimated using the Kaplan-Meier
method. Differences were compared with the log-rank test.
Cumulative incidence functions for relapse/non-response and
toxic death were constructed according to the method reported by
Kalbfleisch and Prentice16 and were compared using Gray test.17
The multivariate analysis of prognostic factors was conducted
using a Cox regression analysis with backward elimination.18
Toxicity was assessed after each treatment phase using the
National Cancer Institute Common Toxicity Criteria (NCI-CTC).19
Differences in the distribution of individual parameters between
subsets of patients were analyzed using the chi-square test or
Fisher exact test for categorized variables and the Mann-Whitney
U test for continuous variables. A P-value <0.05 was considered
statistically significant.
The incidence of toxic deaths was monitored with a Wald
sequential plan assuming a toxic death rate of 1% as acceptable,
based on previous NHL-BFM studies. In an amendment the stop-
ping rule was set to accept a toxic death rate of 2%. Details of the
toxic death monitoring procedure are provided in Online
Supplement 9. 
The analysis was based on follow-up data available as of March
2014. The data were analyzed using SAS version 9.3 (SAS Institute,
Cary, NC, USA).
Signed informed consent was obtained. The study was per-
formed after receiving approval from the responsible ethics com-
mittees and was conducted in accordance with the Declaration of
Helsinki of 1975 and its revision in 2000.
Results
Patients’ enrollment and premature trial closure
When a fifth case of toxic death occurred among 115
patients with a follow-up duration of at least 30 weeks or a
toxic death, patients were no longer enrolled in the study
because the stopping rule was met. After an amendment to
the protocol that included auditing of the participating cen-
ters, advice on the particular toxicity of the induction and
re-induction phases, and setting P0 of the Wald sequential
plan for monitoring the incidence of toxic deaths to 2%
(Online Supplement 9), enrollment was re-opened 9 months
after the initial termination. Enrollment was ultimately
closed 2 years later, when the 12th case of toxic death
occurred among 268 patients with a follow-up duration of
at least 30 weeks or a toxic death. Up to that time point, 351
patients had been assessed for eligibility (Figure 1A), and
319 patients were eligible for study entry and included in
the subsequent analyses. 
Patients’ characteristics
The patients’ characteristics are presented in Table 2. The
diagnoses were T-LBL in 233 (73%) patients, precursor B-
cell LBL (pB-LBL) in 66 patients (21%), mixed phenotype
LBL in 12 patients (4%), and other constellations in eight
patients, as specified in Table 2. 
In 30 patients (9%), the disease stage could not be pre-
cisely determined due to the lack of pre-therapeutic bone
marrow collection and/or lumbar puncture. In 28 cases,
this process was consistent with the recommendation to
postpone invasive measures when a critical mediastinal
tumor syndrome was present and to initiate treatment
immediately. 
Treatment 
Consistent with the protocol, 35 of the 40 patients with
stage I/II tumors received induction, consolidation M and
maintenance therapy, whereas 279 patients with stage III,
IV tumors or an unknown stage received additional re-
intensification therapy. Five of the 40 patients with stage
E. Landmann et al.
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Table 1. Treatment protocol.
Drug                                                    Dose             Administered on days
Cytoreductive pre-phase                                                    
Prednisone                                          60 mg/m2/day        1-7
Methotrexate (it)                                    12 mg*              1
Induction, phase Ia                                                       
Prednisone (oral or iv)                 60 mg/m²/day        8-28, then tapered over 3x3 days
                                                                         versus               
Dexamethasone (oral or iv)        10 mg/m²/day        8-28, then tapered over 3x3 days
Vincristine (iv)                                         1.5 mg/m2           8, 15, 22, 29
                                                                    (max 2 mg)
Daunorubicin (iv over 1 h)                    30 mg/m2            8, 15, 22, 29
E. coli asparaginase (iv over 1 h)     10,000 IU/m2         12, 15, 18, 21, 24, 27, 30, 33
Methotrexate (it)                                      12 mg*              12, 33†
Induction, phase Ib                                                       
Cyclophosphamide‡ (iv over 1 h)     1000 mg/m2          36, 64
Cytarabine (iv)                                         75 mg/m2            38-41, 45-48, 52-55, 59-62
6-Mercaptopurine (oral)                       60 mg/m2            36-63
Methotrexate (it)                                      12 mg*              45, 59
                                                                14-day pause
Consolidation, phase M                                              
6-Mercaptopurine (oral)                       25 mg/m2            1-56
Methotrexate§                                            5 g/m2               8, 22, 36, 50
Methotrexate (it)                                      12 mg*              8, 22, 36, 50
                                                                14-day pause
For stages III and IV only: re-intensification, phase IIa
Dexamethasone (oral or iv)                 10 mg/m2            1-21, then tapered over 3x3 days
Vincristine (iv)                                         1.5 mg/m2           8, 15, 22, 29
                                                                    (max 2 mg)
Doxorubicin (iv over 1 h)                      30 mg/m2            8, 15, 22, 29
E. coli asparaginase (iv over 1 h)     10,000 IU/m2         8, 11, 15, 18
For stages III and IV only: re-intensification, phase IIb
Cyclophosphamide‡ (iv over 1 h)     1000 mg/m2          36
Cytarabine (iv)                                         75 mg/m2            38-41, 45-48
Methotrexate (it)                                      12 mg*              38, 45
6-Thioguanine (oral)                              60 mg/m2            36-49
                                                                14-day pause
Maintenance                                                                   
6-Mercaptopurine (oral)                 50 mg/m²            Daily until 24 months of total
                                                                                                   treatment 
Methotrexate (oral)                           20 mg/m²            Weekly until 24 months of total
                                                                                                   treatment 
                                                                         versus               
6-Mercaptopurine (oral)                   50 mg/m²            Daily until 18 months of total
                                                                                                   treatment 
Methotrexate (oral)                            20 mg/m²            Weekly until 18 months of total
                                                                                                   treatment
iv, intravenous; it, intrathecal. *Doses were adjusted for children <3 years of age. **Randomization
of patients with T-LBL only, with dexamethasone representing the experimental arm. †Additional
doses were administered to central nervous system (CNS)-positive patients and for patients with
blasts in cerebrospinal fluid and <5 cells/µL cerebrospinal fluid on days 18 and 27. In December
2007, the study was amended to state that for children in whom the CNS status was unknown, two
additional doses should be administered on days 18 and 27. ‡With mesna. §Ten percent of the
dose was administered over 30 min and the remaining 90% was administered as a 23.5-h contin-
uous iv infusion. Leucovorin rescue: 30 mg/m2 iv at hour 42 and 15 mg/m2 iv at hours 48 and 54.
The serum methotrexate levels should be <3 mmol/L at hour 36, <1 µmol/L at hour 42, and <0.4
mmol/L at hour 48 after initiation of the methotrexate infusion. §§Randomization of patients with
T-LBL only, with an 18-month total treatment duration as the experimental arm.
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I/II tumors also received re-intensification in violation of the
protocol due to individual decisions. 
Of the 319 patients, 239 were eligible for the randomiza-
tion treatment with prednisone or dexamethasone in induc-
tion phase Ia (Figure 1A). One hundred and eighty-six of
these 239 patients were randomized; 88 were selected to
receive prednisone and 98 were selected to receive dexam-
ethasone, two of whom received prednisone due to indi-
vidual decisions. Of the 53 non-randomized patients, three
received dexamethasone. Of the 80 patients who were not
eligible for randomization, five were given dexamethasone
based on individual decisions. Thus, a total of 215 patients
received prednisone and 104 patients received dexametha-
sone in induction phase Ia.  
Dexamethasone and prednisone in LBL
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Figure 1. Consort flow diagram and flow chart of the EURO-LB02 trial. (A) CONSORT flow diagram. *In 11 patients, the diagnosis of T-LBL was subsequently revised
(precursor B-cell LBL, n=1; biphenotypic/bilineal LBL, n=5; T-NHL not further classified, n=3; undifferentiated lymphoma, n=2). Six of these patients were randomized.
(B) Flow chart of the EURO-LB02 trial. Patients with precurcor B-cell-LBL received the standard arm. *Resulting in a total therapy duration of 18 or 24 months. 
A
B
Outcomes
With a median follow-up period of 6.8 years (range, 3.0-
10.3), the 5-year EFS rate for the 319 eligible patients was
82±2%. Sixty events were reported (Table 2). Twelve
patients (3.8%) died from toxicity. Four patients had not
responded by day 33 of induction therapy, 39 patients
relapsed and five developed secondary cancers. Secondary
malignancies included: acute myeloid leukemia, myelodys-
plastic syndrome progressing to acute myeloid leukemia,
colorectal adenocarcinoma, ALL, and Epstein-Barr virus-
associated lymphoma.
A local lack of response or relapse was the predominant
failure in patients with T-LBL, whereas systemic relapse
and testicular relapse were the predominant sites of failure
in patients with pB-LBL. The median time from diagnosis
to relapse was 12 months (range, 1-77 months) for patients
with T-LBL and 34 months (range, 3-70 months) for
patients with pB-LBL. CNS relapses occurred early (at a
median of 12 months from diagnosis; range, 3-27 months).
All nine patients who had a CNS relapse had received pred-
nisone during induction phase Ia.
The 5-year overall survival rate was 87±2%. The causes
of death in the 41 patients who died were disease progres-
sion or relapse in 27 patients, toxicity in 12 patients and sec-
ondary malignancies in two patients. 
Toxicity
Eight of the 215 patients given prednisone (3.7%) and
four of the 104 patients (3.8%) given dexamethasone in
induction phase Ia died due to toxicity. Five toxic deaths
occurred during induction phase Ia (prednisone, n=2 and
dexamethasone n=3). One patient died in induction phase
E. Landmann et al.
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Table 2. Protocol patients: characteristics and events.
                                                                                                                    Immunophenotype                  
                                                                                        Total                               T-cell                Precursor B-cell      Mixed phenotype          Other*
Total                                                                                            319 (100%)                           233 (73%)                      66 (21%)                       12 (4%)                           8
Male gender                                                                              229 (72%)                            176 (76%)                      40 (17%)                         8 (4%)                            5
Age, range [years]                                                                      0.3-18.8                                  1.0-18.8                          0.3-17.2                          3.8-18.6                     4.1-18.4
Age, median [years]                                                                      8.76                                        8.74                                 8.43                               11.52                          14.35
Age ≥10 years                                                                            139 (44%)                            105 (76%)                      22 (16%)                       7 (5%)                           5
Stage I                                                                                           11 (3%)                                       -                                     11                                    -                                  -
Stage II                                                                                          29 (9%)                                       8                                     18                                    3                                 -
Stage III                                                                                      176 (55%)                                   150                                   20                                    2                                 4
Stage IV                                                                                        73 (23%)                                     49                                   14                                    7                                 3
BM-positive                                                                                 67 (21%)                                     44                                   14                                    6                                 3
CNS-positive                                                                                11 (3%)                                       9                                     1                                     1                                 -
CNS type 3 (blasts detected but <5 cells/mL CSF)            9 (3%)                                        7                                     2                                     -                                  -
CNS not tested                                                                           28† (9%)                                     24                                     3                                     -                                  1
Stage not evaluable                                                                    30 (9%)                                      26                                    3                                     -                                  1
• No pre-therapeutic BM                                                               3                                             3                                      -                                      -                                  -
• No pre-therapeutic LP                                                               22‡                                           18                                     3                                      -                                  1
• No pre-therapeutic BM or LP                                                    5                                             5                                      -                                      -                                  -
B-symptoms                                                                                82 (26%)                                     71                                    6                                     2                                 3
Mediastinal mass                                                                     229 (72%)                                   216                                   4                                     4                                 5
Need for intensive care                                                           35 (11%)                                     34                                     -                                      1                                 -
EVENTS                                                                                                                                                                                                                                                               
Toxic death (n)                                                                         12 (3.8%)                                     8                                     3                                     -                                  1
Non-response (n)                                                                     4 (1.3%)                                      3                                      1                                      -                                  -
Relapse (n)                                                                               39 (12.2%)                                   31                                     7                                      -                                  1
• Local ± new                                                                                  15                                           14                                     -                                      -                                  1
• BM                                                                                                    6                                             5                                      1                                      -                                  -
• CNS                                                                                                  7                                             7                                      -                                      -                                  -
• BM and CNS                                                                                   2                                             1                                      1                                      -                                  -
• BM ± local ± new                                                                         4                                             3                                      1                                      -                                  -
• Testes                                                                                              3                                              -                                      3                                      -                                  -
• Other                                                                                               2                                             1                                      1                                      -                                  -
Second cancer                                                                                   5                                             2                                      3                                      -                                  -
LP: lumbar puncture; CNS: central nervous system; CSF: cerebrospinal fluid; BM: bone marrow. *Immunophenotype not determined, n=2; no lineage-specific markers, n=2; FAB-
L1 cytomorphology but mature B-cell phenotype, n=1; T-non-Hodgkin lymphoma not further classified (lymphoblastic nature could neither be proven nor excluded due to insuf-
ficient material), n=3. †Includes one patient in whom LP was not performed but who was BM-positive and was thus stage IV. Of these 28 patients, three were treated as CNS-positive
(1 due to epidural involvement and 2 due to suspicious cells in the CSF on day 3 or 33 of treatment), 19 were treated as CNS-negative, and five received two additional methotrex-
ate doses (it) during the induction phase; for one patient, there were no data on CNS treatment. Five events (all relapses) occurred in these 28 patients (1 CNS relapse, 1 BM
relapse, 3 local relapses); the CNS relapse occurred in a patient treated as CNS-negative [the first of 11 scheduled methotrexate (it) treatments was omitted]. ‡Does not include
the one patient in whom LP was not performed but who was BM-positive and was thus stage IV.
Ib, two patients died during consolidation phase M, three
patients died during re-induction phase IIa and one patient
died during the maintenance phase. Detailed causes of
death are provided in Table 3. The toxic death rate per
study group ranged from 0% to 9.7%. Some of the partici-
pating study groups had not previously used the BFM strat-
egy. The toxic death rate was higher in study groups that
had not previously used the BFM strategy (4 toxic deaths
among 78 patients, cumulative incidence of toxic death,
5±3%) than in the groups in which the BFM strategy had
already been established prior to the EURO-LB 02 study (8
toxic deaths among 241 patients; cumulative incidence of
toxic death, 3±1%); this difference was not statistically sig-
nificant (P=0.46). 
A total of 65 non-fatal severe adverse events were report-
ed in 51 patients. The number of such events did not differ
significantly between patients receiving prednisone in
induction Ia (19%, 41/215 patients) and those receiving dex-
amethasone (23%, 24/104 patients). The incidence of non-
fatal severe adverse events also did not differ significantly
among the patients randomized to receive either prednisone
or dexamethasone in induction Ia (data not shown). 
Among all patients, 29 of the severe adverse events
occurred during induction Ia [12 in 215 patients receiving
prednisone (6%) and 17 in 104 patients receiving dexam-
ethasone (16%)], three during induction Ib, ten during
consolidation phase M, 16 during re-intensification phase
IIa, four during re-intensification phase IIb and three dur-
ing maintenance. Details are provided in Online
Supplement 10. 
Grade III and IV NCI-CTC toxicities observed in each
treatment phase, with the exception of the maintenance
phase, are shown in Online Supplements 11 and 12. The
most frequently reported toxicities were hematologic tox-
icity, coagulation problems, infection, and liver toxicity.
Hematologic toxicity was the most frequent toxicity
observed during all phases, with the exception of the
cytoreductive prephase. Toxicity due to coagulation and
thrombosis most frequently occurred in induction phase
Ia and re-intensification phase IIa. Regarding the cortico -
steroid administered in induction phase Ia, the following
grade III and IV toxicities were reported significantly more
frequently in patients given dexamethasone than in
patients given prednisone: hematologic toxicity, infection,
stomatitis, thrombosis, arrhythmia and peripheral neuro-
toxicity. Details are given in Online Supplements 11 and 12.
In the subset of patients randomized to receive either
prednisone or dexamethasone in induction phase Ia, only
grade III/IV hematologic toxicity, infection and peripheral
neurotoxicity occurred significantly more frequently in
patients given dexamethasone than in those given pred-
nisone (Online Supplement 13). In the total group and in the
subset of randomized patients, the higher frequency of
grade III/IV toxicities observed in patients receiving dex-
amethasone in induction phase Ia was associated with a
significantly greater delay in the initiation of induction
phase Ib (a median of 4 days for patients receiving dexam-
ethasone in induction phase Ia and a median of 1 day for
patients receiving prednisone in induction phase Ia;
P=0.0003 for the total group, P=0.01 in the subset of ran-
domized patients only; Online Supplement 14). 
Prognostic factors
Results of univariate analyses of variables with possible
impacts on treatment outcomes in the entire group are pre-
sented in Table 4 and by immunophenotypic subgroup in
Online Supplements 15 and 16. 
The patients’ immunophenotypes had no statistically
significant impact on outcomes (Figure 2). The disease
stage had no statistically significant impact on the entire
group or on patients with T-LBL. In the subset of patients
with pB-LBL, stage III disease was associated with a signif-
icant reduction in EFS, whereas the cumulative incidences
of relapse or non-response were not significantly different
(Online Supplement 16). The nine events occurring among
the 20 patients with stage III pB-LBL were four relapses,
Dexamethasone and prednisone in LBL
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Table 3. Treatment-related mortality.
Treatment phase                 TRM (n)           Steroid received         Age at diagnosis      Immuno-                                         Cause of death
                                                                   at time of death                 (years)            phenotype
Induction Ia                                    5                         Prednisone                              2.1                       T-LBL                                                        Septic shock
                                                                                       Prednisone                            15.8                 early B-LBL                       Intracerebral hemorrhage following sinus 
                                                                                                                                                                                                                                   venous thrombosis
                                                                                  Dexamethasone                         2.2                       T-LBL                                     Sepsis (S. aureus, Acinetobacter)
                                                                                  Dexamethasone                         2.5                       T-LBL                            Necrotizing adenovirus enteritis and ARDS
                                                                                  Dexamethasone                         9.7                       T-LBL                        Acute respiratory failure with acute pulmonary
                                                                                                                                                                                                                       edema, coma, and cardiac arrest
Ib                                                       1                                   *                                       9.1                      pB-LBL                        Enterovirus infection, interstitial pneumonia,
                                                                                                                                                                                                                  myocarditis, and pontine myelinolysis
M                                                       2                                   *                                       9.3                      pB-LBL                                                 Multi-organ failure
                                                                                                *                                       0.7                      pB-LBL                                                      Septic shock
IIa                                                      3                    Dexamethasone*                        9.9                       T-LBL                                                         Septicemia
                                                                                 Dexamethasone*                       11.0                      T-LBL                                    Pulmonary aspergillosis and ARDS
                                                                                 Dexamethasone*                       11.6                      T-LBL                           Mycotic infection of the lung and pulmonary 
                                                                                                                                                                                                                                          hemorrhage
IIb                                                      0                                                                                                                                                                                        
Maintenance                                   1                                   †                                       7.5                       T-LBL                                                   Varicella infection
ARDS: acute respiratory distress syndrome; pB-LBL: precursor B-cell lymphoblastic lymphoma; T-LBL: T-cell lymphoblastic lymphoma; TRM: treatment-related mortality. *Received
prednisone during induction phase Ia. †Received dexamethasone during induction phase Ia.
one non-response, one toxic death, and three secondary
malignancies (myeloproliferative disease: n=1, Epstein-
Barr virus associated lymphoma: n=1, and mixed pre-
T/common-ALL: n=1). Performance status 5 (i.e., a need
for intensive care treatment) at diagnosis before the start of
treatment was associated with poor outcomes and a higher
incidence of relapse or non-response in the entire group
and in patients with T-LBL. Performance status at diagnosis
was documented for 232 of 233 patients with T-LBL.
Thirty-four of the 35 patients with performance status 5
had T-LBL. Their outcomes were significantly worse than
those of the 198 patients with T-LBL and performance sta-
tus 1-4: EFS 66±8% versus 85±3%, P=0.003; cumulative
incidence of non-response/relapse 29±8% versus 11±2%,
P=0.006. 
In the univariate analyses, none of the other factors
examined had an impact on outcomes, either in the entire
group or in the subgroups of patients with T-LBL or pB-
LBL. 
In the multivariate analysis (Cox regression with back-
ward elimination) of the entire group,  which included the
variables immunophenotype, age (<10 versus ≥10 years),
gender, stage (<III versus ≥III), bone involvement, bone
marrow involvement, CNS involvement, lactate dehydro-
genase levels (< 2 versus ≥2x the normal value), B-symp-
toms, mediastinal mass, superior vena cava syndrome,
pleural effusion, pericardial effusion, tumor lysis syn-
drome, impaired renal function, and performance status
(<5 versus 5), only a performance status of 5 remained in
the models for EFS (hazard ratio: 3.0; 95% confidence
interval: 1.3-6.9; P=0.01) and for cumulative incidence of
non-response/relapse (hazard ratio: 2.9; 95% confidence
interval: 1.4-6.9; P=0.004). This finding was also true when
the analysis was restricted to only patients with T-LBL: EFS
hazard ratio 3.1; 95% confidence interval: 1.3-7.2; P=0.01,
incidence of non-response/relapse hazard ratio 2.8; 95%
confidence interval: 1.3-6.9; P=0.006).
Patients who received dexamethasone in induction phase
Ia had a lower cumulative incidence of non-response or
relapse than patients who received prednisone, with the
difference being of borderline statistical significance (Table
4). Regarding the site of failure, the cumulative incidence of
CNS relapses at 5 years was 4±1% among the 215 patients
who received prednisone in the induction phase compared
to 0% in the 104 patients who received dexamethasone
(P=0.03), whereas the cumulative incidences of non-CNS
relapse or non-response at 5 years were 10±2% and 9±3%,
respectively (P=0.45). 
E. Landmann et al.
2092 haematologica | 2017; 102(12)
Table 4. Univariate analyses of prognostic factors in all patients.  
                                                                                      N.              EFS (%)          SE (%)                P                  Non-response/          SE (%)     P (Gray)
                                                                                                                                            (log-rank test)    relapse (cumulative
                                                                                                                                                                           incidence (%))
Stage                                                                I                             11                     100                     0                       0.19                                 0                               0                0.39
                                                                          II                            29                      86                      6                                                             10                              6                   
                                                                          III                          176                     78                      3                                                             14                              3                   
                                                                          IV                           73                      88                      4                                                             10                              4                   
                                                                    unknown                     30                      83                      7                                                             17                              7                   
Stage IV                                                  BM+/CNS-                   58                      86                      5                       0.69                                10                              4                0.68
                                                                  BM-/CNS+                    6                       83                     15                                                            17                             17                  
                                                                 BM+/CNS+                   5                      100                     0                                                              0                               0                   
Lactate dehydrogenase                         ≤2 UNL                     203                     81                      3                       0.24                                13                              2                0.46
                                                                     >2 UNL                     110                     85                      3                                                             11                              3                   
                                                                     ≤4 UNL                     285                     82                      2                       0.62                                12                              2                0.76
                                                                     >4 UNL                      28                      86                      7                                                             11                              6                   
Mediastinal tumor                                       no                           90                      82                      3                       0.80                                10                              3                0.64
                                                                         yes                         229                     81                      4                                                             14                              2                   
Pleural effusion                                           no                          165                     83                      3                       0.66                                13                              3                 0.9
                                                                         yes                         154                     81                      3                                                             12                              3                   
Pericardial effusion                                    no                          233                     84                      2                       0.18                                11                              2                0.19
                                                                         yes                          86                      78                      4                                                             16                              4                   
Bone involvement                                       no                          286                     83                      2                       0.51                                12                              2                0.21
                                                                         yes                          33                      76                      7                                                             21                              7                   
B-symptoms (any)                                      no                          237                     83                      2                       0.59                                11                              2                0.13
                                                                         yes                          82                      80                      4                                                             17                              4                   
Performance status *                                  1                           100                     86                      3                      0.055                               9                               3                0.06
                                                                           2                            97                      80                      4                                                             14                              4                   
                                                                           3                            52                      88                      4                                                             10                              4                   
                                                                           4                            34                      82                      7                                                              9                               5                   
                                                                           5                            35                      66                      8                                                             29                              8                   
                                                                       1 to 4                       283                     84                      2                     0.0047                             11                              2               0.003
                                                                           5                            35                      66                      8                                                             29                              8                   
Initial complications, any**                      no                          158                     82                      3                       0.93                                13                              3                0.92
                                                                         yes                         161                     83                      3                                                             12                              3                   
continued on the next page
Discussion 
We report data from 319 children and adolescents suffer-
ing from LBL enrolled in the EURO-LB02 trial. We derived
important conclusions and useful information from this
large multi-group, multinational study, although neither
randomized study questions could be answered in the con-
firmatory analysis because the trial had to be closed prema-
turely due to an excess of toxic deaths. 
Firstly, this trial was instrumental in establishing a large
European network of inter-group collaborators in the field
of childhood and adolescent NHL, which will foster future
progress in the understanding and treatment of this orphan
disease.12
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Acute tumor lysis syndrome                     no                          304                     82                      2                       0.63                                13                              2                0.76
                                                                         yes                          13                      77                     12                                                            15                             10                  
Impaired renal function                            no                          308                     82                      2                       0.60                                13                              2                0.24
                                                                         yes                           9                       89                     10                                                             0                               0                   
Mediastinal tumor with                             no                          183                     81                      3                       0.79                                13                              2                0.94
respiratory impairment                             yes                         134                     83                      3                                                             13                              3                   
Vena cava syndrome                                   no                          285                     82                      2                                                             13                              2                0.23
                                                                         yes                          32                      78                      7                       0.52                                 6                               4                   
Immunophenotype                                       T                           233                     82                      3                       0.27                                14                              2                0.33
                                                                         pB                           66                      80                      5                                                             11                              4                   
                                                                      mixed                        12                     100                     0                                                              0                               0                   
Immunophenotype                                      T                           199                     82                      3                       0.64                                13                              2                0.40
in stages III/IV only                                     pB                           34                      67                      8                                                             18                              7                   
                                                                     mixed                         9                      100                     0                                                              0                               0                   
Age (years)                                                  <10                         180                     81                      3                       0.59                                12                              2                0.86
                                                                        ≥10                         139                     83                      3                                                             13                              3                   
                                                                        <15                         286                     82                      2                       0.72                                12                              2                0.41
                                                                        ≥15                          33                      78                      7                                                             19                              7                   
Gender                                                         male                        229                     82                      3                       0.65                                14                              2                0.27
                                                                     female                       90                      81                      4                                                              9                               3                   
age>10                             male                         99                      84                      4                       0.57                                15                              4                0.44
                                                                     female                       40                      82                      6                                                              8                               4                   
age>15                             male                         24                      78                      9                       0.92                                22                              9                0.51
                                                                     female                        9                       78                     14                                                            11                             11                  
Corticosteroid administered in Ia         Pred                        215                     80                      3                       0.11                                15                              2                0.09
                                                                        Dex                         104                     86                      3                                                              9                               3                   
Treatment delay on day 8 –                      ≤34                         227                     84                      2                       0.55                                12                              2                0.48
the beginning of phase Ib (days)           >34                          74                      86                      4                                                             10                              3                   
EFS: event-free survival; SE: standard error; BM+,: bone marrow positive, BM-: bone marrow negative; CNS+: central nervous system positive; CNS-: central nervous system negative;
UNL: upper normal limit; T-LBL: T-lymphoblastic lymphoma; pB-LBL: precursor B-cell lymphoblastic lymphoma; Pred: prednisone; Dex: dexamethasone;*i.e., performance status
at diagnosis before start of treatment, with a performance status of 5 defined as need for admission to intensive care unit. Intensive Care Unit admission was at the discretion of
the responsible physician; **i.e., acute tumor lysis syndrome and/or one or more of the following conditions: impaired renal function, mediastinal tumor with respiratory impair-
ment, vena cava syndrome, cardiac insufficiency, paraplegia, life-threatening sepsis, life-threatening bleeding, and respiratory impairment due to pleural effusions.
                                                                                      N.              EFS (%)          SE (%)                P                  Non-response/          SE (%)     P (Gray)
                                                                                                                                            (log-rank test)    relapse (cumulative
                                                                                                                                                                           incidence (%))
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Figure 2. The 5-year event-free survival (EFS,
from diagnosis) of protocol patients with T-
cell, precursor B-cell and biphenotypic lym-
phoblastic lymphoma. EFS: event-free sur-
vival SE: standard error. The median time to
an event was 0.9 and 2.3 years (P=0.21) in
patients suffering from T-LBL and pB-LBL,
respectively.
The reference treatment arm of the EURO-LB02 trial was
the protocol of the NHL-BFM90 study, except that preven-
tive cranial irradiation was omitted.5 The outstanding result
of a 5-year EFS of 90% for patients with T-LBL reported in
the BFM group NHL-BFM90 trial5 was not replicated in the
inter-group EURO-LB02 study. The lower 5-year EFS of
82% for patients with T-LBL in the EURO-LB02 trial was
primarily due to higher rates of toxic death (0% in NHL-
BFM 90, 3.4% in EURO-LB02) and CNS relapse (cumula-
tive incidence of CNS relapse at 5 years: 0% in NHL-BFM
90 and 3±1% in EURO-LB02; P=0.05), but the cumulative
incidence of non-CNS relapse/non-response was compara-
ble (cumulative incidence of non-CNS relapse/non-
response at 5 years: 8±3% in NHL-BFM 90 and 10±2% in
EURO-LB02; P=0.27). 
The higher incidence of toxic deaths in the EURO-LB02
trial compared to the previous NHL-BFM studies3,5 cannot
be clearly ascribed to a distinct reason.
At the premature stopping of the EURO-LB02 trial, the
rate of toxic deaths in the 319 enrolled patients was 3.8%
(no further toxic deaths occurred during follow-up) and was
higher than expected from previous BFM group studies,
since no toxic deaths were observed in the NHL-BFM90
trial5 and the rate of such deaths in the NHL-BFM95 trial
was 1.3%.3 Infection was the most frequent cause of death,
and induction phase Ia and re-intensification phase IIa were
clearly the most dangerous phases of this therapy. 
According to several ALL studies, compared to pred-
nisone, dexamethasone increases the toxicity of induction
therapy.20-23 In the randomized ALL AIEOP-BFM 2000 trial,
toxic deaths also occurred significantly more frequently in
patients who were randomized to receive dexamethasone
in the induction phase than in patients randomized to
receive prednisone.24
In the EURO-LB02 study, there was no significant differ-
ence in the number of toxic deaths between patients receiv-
ing dexamethasone or prednisone in induction phase Ia,
either in the number of toxic deaths observed during induc-
tion phase Ia itself or in the total number of toxic deaths.
However, non-fatal grade III and IV toxicity occurred signif-
icantly more frequently in patients receiving dexametha-
sone, resulting in a significant delay in subsequent treat-
ment phases. 
Some of the participating study groups had not previous-
ly used the BFM strategy. Although the toxic death rate was
higher in those study groups than in the groups in which
the BFM strategy had been established prior to the EURO-
LB02 study, this difference was not statistically significant.
Nevertheless, familiarity with treatment protocols should
be considered when planning further multi-group trials.
An unexpectedly high number of CNS relapses was
observed in the EURO-LB02 study; all of these relapses
occurred in patients who had received prednisone during
induction phase Ia. The prevention of CNS relapse
remains an unsolved problem. The A5971 trial by the
Children’s Oncology Group (COG)25 showed comparable
outcomes when CNS prophylaxis depended on the fre-
quent delivery of intrathecal methotrexate compared to
high-dose methotrexate. Thus, additional intrathecal
methotrexate applications might represent a promising
approach. Additional high-dose methotrexate infusions
are another promising approach. In the SIOP LMT96
trial,26 ten courses of high-dose methotrexate (3 g/m2) were
administered. Only one of the 79 trial participants experi-
enced a CNS relapse. The administration of additional
high-dose methotrexate infusions during the maintenance
phase has also been shown to treat CNS disease effective-
ly in patients with T-LBL.7 Based on our data, the use of
dexamethasone during induction phase Ia is more effica-
cious than prednisone in preventing CNS relapse, but is
more toxic. The higher rate of infections observed in the
dexamethasone group is of particular concern. This find-
ing is consistent with the results from several,20-24,27 but not
all,28,29 trials in patients with ALL. However, some studies
have reported higher EFS and overall survival, despite
higher rates of severe infection, in patients treated with
dexamethasone than in patients treated with pred-
nisone.23,27 An important point to consider is the dose
equivalence between dexamethasone and prednisone
with regard to anti-tumor efficacy and toxicity. Data
regarding these drugs’ relative anti-leukemic activity are
inconsistent, and data on their toxic potential are lack-
ing.30,31 In animal models, the cerebrospinal fluid penetra-
tion of dexamethasone is greater than that of prednisone.32
Thus, a dose of dexamethasone lower than 10 mg/m2/day,
which was used in this study, might be less toxic but more
efficacious in protecting against CNS toxicity, as has been
shown in children suffering from ALL.29 A shorter duration
of dexamethasone treatment might be another reasonable
option for taking advantage of the efficacy of dexametha-
sone at a tolerable toxicity.
The administration of dexamethasone for 2 weeks versus
prednisone for 4 weeks in patients with high-risk precursor-
B-ALL during induction therapy was recently shown to
result in better efficacy of dexamethasone in patients
younger than 10 years, but not in patients aged 10 years or
older. The rate of CNS relapses was lower in patients treat-
ed with dexamethasone.33
In the EURO-LB02 study, patients with stage I or II dis-
ease did not receive re-intensification therapy. Given the
biological similarities between LBL and ALL, we reasonably
asked whether patients with LBL would also benefit from
delayed intensification therapy, like patients with ALL.34
Notably, the 5-year EFS rates for patients with stage I/II dis-
ease were 90% in both the EURO-LB02 study (5-year EFS,
90±5%, n=40) and the COG A5971 study35 (5-year EFS,
90%, n=51). However, delayed intensification therapy for
patients with stage I/II disease was only administered in the
COG A5971 study, resulting in a higher cumulative dose of
anthracycline and cyclophosphamide.
Improving the outcome for pediatric/adolescent patients
with LBL remains a challenge. The toxic death rate of 3.8%
in our study indicates a critical balance between treatment
efficacy and risks. However, the salvage of relapsed patients
has been shown to be poor.1,8,25 Thus, treatment optimiza-
tion involves finding highly predictive markers that enable
the early identification of patients who are not curable with
current treatments. These patients could be designated to
alternative treatment strategies, whereas all others could be
protected from the risk of experimental treatments.
We performed a comprehensive analysis of variables
with possible impacts on outcomes in this large group of
children who were classified and treated uniformly.
Apart from localized versus advanced stage, the only vari-
able associated with decreased EFS was a poor performance
status at diagnosis. Researchers have not clearly determined
whether a poor performance status reflects disease with a
more aggressive biology or difficulties in treatment realiza-
tion. In any case, this parameter is not very useful for risk
stratification. Nevertheless, this finding might alert physi-
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cians to pay special attention to these patients. 
The EURO-LB02 study contributed reliable up-to-date
information on the classification of patients with LBL. A
central pathology review was performed in as many as
90.4% of the cases. Additional detailed immunohistochem-
ical analyses of this large series were performed by the
European Childhood Lymphoma Panel. The results enabled
the development of a step-wise and material-sparing diag-
nostic approach as a complementary strategy to the strate-
gy recommended by the World Health Organization.36
Based on this reliable classification, we also showed that
the immunophenotype lineage had no additional impact on
outcome. A novel observation from the EURO-LB02 study
was that lineage promiscuity was present in as many as 4%
of all patients diagnosed with LBL. Given the aggressive
course observed in children with leukemia of an ambiguous
lineage,37 the outcomes of the 12 patients with mixed phe-
notype LBL in the EURO-LB02 study were rather favorable,
with no events observed among this subgroup. 
The prognostic power of new biomarkers must be evalu-
ated for the standardized classification and treatment of
patients. NOTCH1 and FBXW7 mutations38,39 and loss of
heterozygosity at chromosome 6q38,40 were recently shown
to be promising prognostic biomarkers of pediatric T-LBL.
Other candidates for prospective evaluation may be param-
eters of the kinetics of the response to treatment, such as
those determined by positron emission tomography and
minimal disseminated disease and its monitoring during
treatment.41,42 The network of collaborators established in
the EURO-LB02 study may provide a platform for this pur-
pose. 
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